![Sven Rohmann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sven Rohmann
Presidente presso Inprother ApS
Posizioni attive di Sven Rohmann
Società | Posizione | Inizio | Fine |
---|---|---|---|
Center for Molecular Medicine (Sweden) | Corporate Officer/Principal | - | - |
Tcer AB | Corporate Officer/Principal | - | - |
Inprother ApS
![]() Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | Presidente | 24/05/2023 | - |
Storia della carriera di Sven Rohmann
Precedenti posizioni note di Sven Rohmann
Società | Posizione | Inizio | Fine |
---|---|---|---|
MENDUS AB | Amministratore Delegato | 28/08/2020 | 16/03/2021 |
HELIX BIOPHARMA CORP. | Direttore/Membro del Consiglio | 18/12/2013 | 18/01/2016 |
Amministratore Delegato | 29/03/2016 | 31/03/2017 | |
Presidente | 18/01/2016 | 01/12/2017 | |
Independent Dir/Board Member | 18/12/2013 | 01/12/2017 | |
Pantec Biosolutions AG
![]() Pantec Biosolutions AG Drugstore ChainsRetail Trade Pantec Biosolutions AG provides laser microporation based transdermal drug delivery services. Its technology can be used for transdermal delivery, intradermal delivary, epidermal delivery, infertility patches, and aesthetic dermatology. The company was founded by Christof Böhler, Herbert Zech, Reinhard Braun, Werner Braun, and Thomas Bragagna in 2006 and is headquartered in Ruggell, Liechtenstein. | Corporate Officer/Principal | - | - |
Helix Polska Sp zoo
![]() Helix Polska Sp zoo Pharmaceuticals: MajorHealth Technology Helix Polska Sp zoo develops therapeutic products. The company is based in Warsaw, Poland. | Presidente | 29/03/2016 | - |
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - | - |
Nextech Invest AG
![]() Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Corporate Officer/Principal | - | - |
░░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░ ░░░░ | ░░░░░░░░ | - | - |
░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Sven Rohmann
Erasmus University Rotterdam | Doctorate Degree |
The Johannes Gutenberg University of Mainz | Doctorate Degree |
Kellogg School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
Svezia | 5 |
Stati Uniti | 4 |
Svizzera | 4 |
Posizioni
Corporate Officer/Principal | 7 |
Chief Executive Officer | 6 |
Chairman | 4 |
Settori
Health Technology | 10 |
Consumer Services | 4 |
Finance | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 6 |
---|---|
LIFEMD, INC. | Health Services |
VIVESTO AB | Health Technology |
HELIX BIOPHARMA CORP. | Health Technology |
ADIUVO INVESTMENTS S.A. | Health Technology |
ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
MENDUS AB | Health Technology |
Aziende private | 11 |
---|---|
Pantec Biosolutions AG
![]() Pantec Biosolutions AG Drugstore ChainsRetail Trade Pantec Biosolutions AG provides laser microporation based transdermal drug delivery services. Its technology can be used for transdermal delivery, intradermal delivary, epidermal delivery, infertility patches, and aesthetic dermatology. The company was founded by Christof Böhler, Herbert Zech, Reinhard Braun, Werner Braun, and Thomas Bragagna in 2006 and is headquartered in Ruggell, Liechtenstein. | Retail Trade |
Helix Polska Sp zoo
![]() Helix Polska Sp zoo Pharmaceuticals: MajorHealth Technology Helix Polska Sp zoo develops therapeutic products. The company is based in Warsaw, Poland. | Health Technology |
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Nextech Invest AG
![]() Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Finance |
Ganymed Pharmaceuticals AG
![]() Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany. | Health Technology |
Burrill LLC
![]() Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Finance |
Biovision AG | |
ImVisioN GmbH
![]() ImVisioN GmbH Miscellaneous Commercial ServicesCommercial Services ImVisioN GmbH provides research in intralymphatic immunotherapy. It is a biotechnology company which specializes the use of intralymphatic immunotherapy to develop treatments for major allergies. Its product, IVN201, is a MAT immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. The company was founded in 2005 and is headquartered in Hanover, Germany. | Commercial Services |
Center for Molecular Medicine (Sweden) | |
Tcer AB | |
Inprother ApS
![]() Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | Health Technology |
- Borsa valori
- Insiders
- Sven Rohmann
- Esperienza